Pneumococcal Vaccines Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 9.04 Bn

Forecast Year, 2035

USD 16.68 Bn

CAGR, 2026 - 2035

6.32%

Report Coverage

Global

What is the Pneumococcal Vaccines Market Size?

The global pneumococcal vaccines market size was calculated at USD 9.04 billion in 2025 and is predicted to increase from USD 9.61 billion in 2026 to approximately USD 16.68 billion by 2035, expanding at a CAGR of 6.32% from 2026 to 2035.The pneumococcal vaccines market has been growing lately due to the growing prevalence of Streptococcus pneumoniae infection, leading to issues such as pneumonia, meningitis, and bloodstream infections. The market also observes growth due to rising global awareness and government-led immunization programs with the motto to eradicate the harmful disease.

Key Highlights of the Pneumococcal Vaccines Market

• North America led the global pneumococcal vaccines market with the largest market share of 73% in 2025.
• The Asia Pacific is observed to be the fastest-growing region in the foreseen period.
• By vaccine type, the pneumococcal conjugate vaccine segment led the global market in 2025.
• By vaccine type, the pneumococcal polysaccharide vaccine segment is observed to be the fastest-growing segment in the forecast period.
• By end use, the public sector led the pneumococcal vaccines market in 2025.
• By end use, the private sector is observed to be the fastest growing in the foreseen period.
• By product, the Prevnar 13 segment led the global pneumococcal vaccines industry in 2025.
• By product, the PNEUMOSIL segment is observed to be the fastest growing in the foreseen period.

What is the Pneumococcal Vaccines Market?

The pneumococcal vaccines help to fight against the harmful and dangerous infection caused by Streptococcus pneumoniae bacteria, further causing pneumonia, meningitis, and major bloodstream infections. Such issues are highly observed in children and adults with weak immunity, hampering their health. Hence, higher demand for vaccination to deal with such major infections is one of the major factors fueling the growth of the market. Such vaccines are cost-effective and are also provided under government-based vaccination programs in various regions. Hence, it also helps to propel the growth of the market. Technological innovations are helpful to shift from lower valency vaccines to higher valency formulations, further fueling the growth of the market.

Role of Technology in the Growth of the Pneumococcal Vaccines Market

Technological advancements have a major impact on the growth of the market. Technological advancements helpful for the manufacturing of next-generation vaccines, such as PCV15 and PCV20, along with the application of new manufacturing techniques, also help to fuel the growth of the market. Such vaccines can induce herd immunity and superior efficacy in children, which also helps to fuel the growth of the market.

Availability of advanced vaccines to deal with a broader range of serotypes is another major factor propelling the growth of the market. Technological advancements are helpful to stability and immunogenicity, and the help of molecular weight reduction also aids the growth of the market. Generative AI is helpful to speed up clinical trials, predict immune responses, and optimize antigen design, and also helps propel the growth of the market.

Pneumococcal Vaccines Market Trends

• Major Shift towards Advanced Vaccines- A major shift towards advanced vaccinations to get broader protection from major serotypes is one of the major factors for the growth of the market.
• Adult Immunization- increasing guidelines focusing on adult immunization, ranging from 50 years and above, to lower the requirement for vaccination, is another major factor for the growth of the market.
• Cost Effectiveness- easy availability and cost-effectiveness of pneumococcal vaccines are helpful for underdeveloped and developed regions to deal with such disastrous infections, also helping to propel the growth of the market.

Segmental Insight

Vaccine Type Insight

The pneumococcal conjugate vaccine segment led the global pneumococcal vaccines market in 2025, as the vaccine helps to fight against the harmful and dangerous pneumococcal disease, which generally impacts children until the age of 5. If the disease is not treated on time, then it may also prove fatal. The vaccine helps to fight the most common serotypes of Streptococcus pneumoniae, the bacterium responsible for pneumonia, meningitis, and other hazardous infections. Government vaccine initiatives to boost the vaccination rate and eliminate the hazardous infection are another major factor propelling the growth of the market.

The pneumococcal polysaccharide vaccine segment is observed to be the fastest growing in the foreseen period, as the vaccine helps in the generation of antibodies that help to kill bacteria through opsonization or phagocytosis. The segment also observes growth as the vaccine is derived from the capsular polysaccharide of Streptococcus pneumoniae, which causes pneumonia and other similar infections. The segment also includes purified preparations of pneumococcal capsular polysaccharide containing polysaccharide antigens, further fueling the growth of the pneumococcal vaccines market in the foreseeable period.

End Use Insight

The public sector segment led the global market in 2025 due to the dominance of domains such as healthcare, hospitals, and clinics, which made the pneumococcal vaccines helpful for the growth of the market. The high prevalence of harmful diseases caused by the pneumococcal bacteria, leading to growing government vaccination initiatives, also helps to fuel the growth of the market. The cost-effectiveness observed with the help of such vaccination programs is another major factor fueling the growth of the market. The spread of hazardous infections and diseases such as pneumonia, sepsis, and meningitis is also a major driver of the growth of the market. If such conditions are not treated at the right time, they also prove to be fatal. Hence, such factors altogether help to propel the growth of the market.

The private sector segment is observed to be the fastest growing in the foreseen period, as the private healthcare sector helps to provide personalized treatment and advanced care to deal with the root cause of any infection or disease, which is helpful for the growth of the market. Private healthcare sectors are a more convenient option for patients who prefer treatment in private and familiar settings, which will help propel the growth of the market in the foreseeable period.

Such sectors also have the latest and advanced vaccinations, such as pneumococcal vaccines, to treat patients in the earliest possible time. Such settings are highly preferable for individuals with hectic lifestyles and who do not have much time to wait for a long waiting period, unlike public healthcare facilities, which are helpful for the growth of the pneumococcal vaccines market in the foreseeable period.

Product Insight

The Prevnar 13 segment led the global pneumococcal vaccines industry in 2025, as the segment highlights the included vaccines such as Prevnar 13 and Prevnar 20. Such vaccines help to fight against the pneumococcal diseases, which is helpful for the growth of the market. Such vaccines are helpful for active immunization in children aged from 6 weeks to 5 years, along with adults aged 18 years and older, further aiding the growth of the market. The segment also observes growth due to its easy global availability, strong uptake in children as well as the adult population, and its higher usage in national immunization programs. The segment also focuses on protecting children from otitis media caused by such serotypes. Hence, such factors altogether help to fuel the growth of the market.

The PNEUMOSIL segment is observed to be the fastest growing as it helps to target serotypes that are most likely to cause Invasive Pneumococcal Disease (IPD). The segment helps to match the cost-effectiveness as per the individual's need to fight against such serotypes, further fueling the growth of the market in the foreseen period. The segment is highly useful in underdeveloped and developing nations due to its cost-effectiveness, further propelling the growth of the market. It is an ideal alternative for existing pneumococcal diseases for children and adults, helpful for the market's growth. Along with being cost-effective, the vaccine is also WHO pre-qualified, further aiding the growth of the pneumococcal vaccines market in the foreseeable period.

Regional Insights

How Big is the North America Pneumococcal Vaccines Market Size?

The North America pneumococcal vaccines market size is estimated at USD 6.60 billion in 2025 and is projected to reach approximately USD 12.26 billion by 2035, with a 6.39% CAGR from 2026 to 2035.

North America Pneumococcal Vaccines Market Trends

North America led the global pneumococcal vaccines market in 2025 majorly due to government-led vaccination programs in the region on a serious note with the motto to eliminate the hazardous infection from children and adults. The consumer-centric reimbursement policies and presence of major key players in the healthcare segment of the region, such as Pfizer and Merck, also help to fuel the growth of the market. The market is also observed to grow due to the dominance of essential vaccinations such as PCV13, PCV15, and PCV20, useful for the paediatric and adult population. Advanced healthcare infrastructure and advanced awareness regarding the issues caused by the pneumococcal diseases also help to fuel the growth of the market.

What is the Size of the U.S. Pneumococcal Vaccines Market?

The U.S. pneumococcal vaccines market size is calculated at USD 4.95 billion in 2025 and is expected to reach nearly USD 9.26 billion in 2035, accelerating at a strong CAGR of 6.46% between 2026 and 2035.

U.S. Pneumococcal Vaccines Market Trends:

The U.S. has a major contribution to the growth of the market due to growing pneumococcal diseases and infections in the region, leading to a high mortality rate of children and adults. The infection also caused lifelong physical disabilities and other similar issues in the region, leading to extensive demand for pneumococcal vaccines, fueling the growth of the market. Hence, government-based vaccination programs and the private healthcare sector make a major contribution to the growth of the market in the region.

Why is the Asia Pacific Considered to be the Fastest-growing Region in the Foreseeable Period?

Asia Pacific is observed to be the fastest-growing region in the foreseen period, mainly due to rising awareness about pneumococcal diseases and the importance of vaccines related to the same. The growing pneumococcal diseases and infections in major countries of the region are another major factor propelling the growth of the pneumococcal vaccines market in the foreseeable period. Growing vaccine manufacturers and the growth of local production facilities in the region to lower import dependency are other major factors fueling the growth of the market. Rising government immunization function is also a vital factor for the growth of the market in the region.

China Pneumococcal Vaccines Market Trends

China has a major contribution to the growth of the market due to the availability of different types of essential vaccines helpful in fighting the pneumococcal diseases and infections. The market also observes growth due to a growing aging population, increasing awareness of the spread of the infection, rising healthcare expenditure, and easy availability of domestic options. Improving healthcare infrastructure and R&D of the region is another major factor propelling the growth of the pneumococcal vaccines market in the foreseeable period.

Pneumococcal Vaccines Market Value Chain Analysis

• R&D

the R&D department involves the manufacturing of advanced pneumococcal vaccines to cover more strains of Streptococcus pneumoniae bacteria, fueling the growth of the market.

• Clinical Trials and Regulatory Approvals

clinical trials of pneumococcal vaccines and approvals from major regulatory frameworks such as the FDA and the US FDA also help to fuel the growth of the market.

• Formulation and Final Dosage Preparation

the market also observes growth due to technological advancements, which helps enhance the valency of pneumococcal vaccines, helpful to deal with the hazardous infections and diseases.

• Distribution to Hospitals, Pharmacies

bulk distribution of pneumococcal vaccines to prevent the spread of the disease and lower the mortality rate, because it also helps to elevate the growth of the market.

• Patient Support and Services

major shift towards high valency conjugate vaccines and expansion of adult immunization programs helps to fuel the growth of the market.

Who are the Major Players in the Global Pneumococcal Vaccines Market?

The major players in the pneumococcal vaccines market include Serum Institute of India Pvt. Ltd., CSL, Sanofi, GSK plc, Merck & Co., Inc., Pfizer Inc., Walvax Biotechnology Co., Ltd, Beijing Minhai Biotechnology Co., Ltd

Segments Covered in the Report

By Vaccine Type

• Pneumococcal Conjugate Vaccine
• Pneumococcal Polysaccharide Vaccine

By Product

• Prevnar 13
• Synflorix
• Pneumovax 23
• VAXNEUVANCE
• PNEUMOSIL
• Other Products

By End-use

• Public Sector
• Private Sector

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa